P1034 (VERSION 10) A COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND PROTEASE-S
P1034 (VERSION 10) A COMPARATIVE TRIAL OF PROTEASE-CONTAINING AND PROTEASE-S
批准号:
7374982
负责人:
William Thomas Shearer
金额:
$0.58万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Adolescents recently diagnosed with human immunodeficiency virus (HIV) represent a select population whom, by virtue of their age, are likely to have been infected within the last few years. Frequently, they are reluctant to engage in ongoing medical care and are less likely than adults to follow through with medical appointments and to adhere to medication schedules. Based on unpublished data from PACTG 381, only 54% of adolescents receiving highly active antiretroviral therapy (HAART) had undetectable viral loads at 16 weeks. These disappointing results occurred despite the fact that the majority of subjects were enrolled at sites that had received additional funds through the adolescent initiative to enhance their ability to recruit and retain adolescents on clinical trials. According to the 2005 International AIDS Society-USA Panel (IAS-USA) revised guidelines for initiating antiretroviral therapy in adults and adolescents, therapy is recommended for individuals with a viral load of greater than 100,000 copies/ml and/or CD4 counts less than 350. This allows for the deferral of therapy in adolescents who do not qualify for treatment. Advantages to delaying therapy include opportunities for interventions that may improve adherence when the patients begin treatment. Therapeutic Regimens Enhancing Adherence in Teens (TREAT) is an adolescent-focused, multifaceted program to promote long-term adherence to HAART. The program is based on the Stages of Change (SOC) Model of behavior change designed by Prochaska and DiClemente (Prochaska and DiClemente, 1986). In this model, individuals move cyclically through a series of stages (precontemplation, contemplation, preparation, action, and maintenance) as they adopt a new behavior. TREAT consists of staging the adolescent and tailoring each stage of readiness for change with a specific intervention appropriate to that stage. The Adolescent Medicine HIV/AIDS Research Network (AMHARN) developed the materials used in TREAT. The TREAT program is designed primarily for treatment naive HIV infected youth, and strives to prepare them for the successful initiation of long-term adherence to HAART through an intensive eight-week program. The TREAT program includes a guidance manual for clinicians, two videotapes, an information booklet, and a set of five audiotapes for the adolescent. Adolescents are staged using a standard questionnaire and then offered the intervention corresponding to that stage. They are re-staged at every clinic visit. The clinic staff works individually with each youth to determine the obstacles that interfere with full adherence and help them develop the necessary skills to promote a successful behavior change. TREAT was incorporated as an optional component of PACTG 381. However, PACTG 381 did not collect information on whether the TREAT intervention was utilized by specific sites or by individual patients. The use of TREAT as it is written or a modified version is recommended by the P1034 team. Two relatively simple HAART regimens to include two NRTIs in adolescents who require therapy will be compared. We will compare a PI-containing (twice-daily lopinavir/ritonavir (Kaletra)) and a PI-sparing (daily efavirenz (Sustiva)) regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PACTG P1026S (VERSION 20), PHARMACOKINETIC PROPERTIES OF ANTIRETROVIRAL DRUG
-
批准号:8356662
-
项目类别:
-
资助金额:$4.13万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
A5240 (VERSION 10) A PHASE II STUDY TO EVALUATE THE IMMUNOGENICITY AND SAFETY
-
批准号:8356728
-
项目类别:
-
资助金额:$2.64万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
IMPAACT 1077HS (VS 10) HAART STANDARD VERSION OF THE PROMISE STUDY
-
批准号:8356740
-
项目类别:
-
资助金额:$0.79万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
Baylor College of Medicine Clinical Trial Unit
-
批准号:8138733
-
项目类别:
-
资助金额:$15.35万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC
-
批准号:8356681
-
项目类别:
-
资助金额:$10.38万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN
-
批准号:8356734
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
PH 201 MEMORY FUNCTIONING IN CHILDREN AND ADOLESCENTS WITH PERINATAL HIV
-
批准号:8356748
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1088 (VERSION 10) A PHASE II STUDY TO ASSESS THE SAFET
-
批准号:8356737
-
项目类别:
-
资助金额:$1.14万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1066 (VERSION 10) A PHASE I/II, MULTICENTER, OPEN-LAB
-
批准号:8356688
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
DURATION OF HUMAN PAPILLOMA VIRUS (HPV) TYPE-SPECIFIC ANTIBODY
-
批准号:8356754
-
项目类别:
-
资助金额:$0.26万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
H-19197 PHACS PH 200 ADOLESCENT MASTER PROTOCOL (AMP)
-
批准号:8356682
-
项目类别:
-
资助金额:$8.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: P1025 PERINATAL CORE PROTOCOL VERSION 10
-
批准号:8356654
-
项目类别:
-
资助金额:$11.17万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
A5241 (VERSION 10) THE OPTIMIZED TREATMENT THAT INCLUDES OR OMITS NRTIS
-
批准号:8356712
-
项目类别:
-
资助金额:$0.53万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF Q
-
批准号:8356683
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
IMPAACT P1089 (VERSION 10) A LABORATORY STUDY TO ASSESS THE IMMUNOGENICITY
-
批准号:8356738
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
Clinical Research Core
-
批准号:7930006
-
项目类别:
-
资助金额:$24.01万
-
财政年份:2010
-
负责人:William Thomas Shearer
-
依托单位:
PHACS PH 100 SURVEILLANCE MONITORING FOR ART TOXICITIES STUDY IN HIV-UNINFEC
-
批准号:8166692
-
项目类别:
-
资助金额:$9.72万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT 1065 PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QU
-
批准号:8166695
-
项目类别:
-
资助金额:$1.48万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: PACTG 390-COMBINATION ANTIRETROVIRAL REGIMENS IN ANTIRETROVIRAL
-
批准号:8166651
-
项目类别:
-
资助金额:$0.58万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
CLINICAL TRIAL: IMPAACT P1086 (VS 10) A PHASE II STUDY TO ASSESS THE SAFETY AN
-
批准号:8166748
-
项目类别:
-
资助金额:$1.24万
-
财政年份:2009
-
负责人:William Thomas Shearer
-
依托单位:
国内基金
海外基金
三维椭圆问题 P 和 H-P Version 有限元法理论及其在工程中的应用研究
-
批准号:11261026
-
项目类别:地区科学基金项目
-
资助金额:52.0万元
-
批准年份:2012
-
负责人:张建铭
-
依托单位:
S-version有限元法及三维复合型裂纹扩展研究
-
批准号:11102158
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2011
-
负责人:谢伟
-
依托单位: